Security key
87975F104
Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)
CUSIP: 87975F104
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / Common Stock, no par value
- Total 13F shares
- 79,917
- Total 13F value
- $413,466
- Share change
- +79,917
- SEC-reported price per share
- $5.15
- Number of holders
- 7
- Value change
- +$413,466
- Number of buys
- 7
- Shares outstanding
- 34,382,284
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
7
Top holders
7
TELO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2024
Telomir Pharmaceuticals, Inc. SEC filings
Telomir Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87975F104
Recent filing periods:
Ownership snapshot
Top reported holders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Christopher Chapman MD
Disclosed value leader
Christopher Chapman MD
Comparable rows
0/6
Latest evidence
08 Feb 2024
3/4/5
Highest disclosed value: $6,048,782
6 rows are not safely comparable across share classes.
Quick read
Christopher Chapman MD has the largest disclosed position value at $6.05M.
0 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Christopher Chapman MD's linked filing trail.
Disclosed position value
Top 5
Christopher Chapman MD
$6.05M
Craig Eagle
$3.02M
Nathen Fuentes
$627K
Bradley Kroenig
$302.4K
Hugh Mccoll III
$302.4K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Christopher Chapman MD |
3/4/5
CEO & Chairman, Director
|
—
class O/S missing
|
$6,048,782
975,610 shares
|
— | 08 Feb 2024 |
| Craig Eagle |
3/4/5
Director
|
—
class O/S missing
|
$3,024,391
487,805 shares
|
— | 08 Feb 2024 |
| Nathen Fuentes |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
$627,031
101,134 shares
|
— | 08 Feb 2024 |
| Bradley Kroenig |
3/4/5
Director
|
—
class O/S missing
|
$302,442
48,781 shares
|
— | 08 Feb 2024 |
| Hugh Mccoll III |
3/4/5
Director
|
—
class O/S missing
|
$302,442
48,781 shares
|
— | 08 Feb 2024 |
| Talhia Tuck |
3/4/5
Director
|
—
class O/S missing
|
$302,442
48,781 shares
|
— | 08 Feb 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
7
Shares
79,917
Rows available
7
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q1 2026 Across Filers
Q1 2026 holders
27
Q1 2024 holders
7
Holder diff
-20
| Investor | Q1 2026 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend